Barriers to antiviral treatment in hepatitis C infected intravenous drug users

Neuropsychopharmacologia Hungarica

Volumn 12, Issue 4, 2010, Pages 459-462

  Gazdag, Gábor ^a   Horváth, Gergely ^b   Szabó, Olga ^a   Ungvari, Gabor S ^c  

^a Szent Istvan and Szent Laszlo Hospitals   (Hungary)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

^c GRAYLANDS HOSPITAL   (Australia)

Author keywords

Antiviral treatment; Barriers; Drug addiction; Hepatitis C infection

Indexed keywords

ANTIVIRUS AGENT;

ABSTINENCE; ADULT; ARTICLE; FEMALE; HEALTH CARE UTILIZATION; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; HUNGARY; MALE; MEDICAL RECORDS; MEDICATION ADHERENCE; OPIATE SUBSTITUTION TREATMENT; POLYMERASE CHAIN REACTION; PRISONERS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 78651358351     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Edlin BR. Prevention and treatment of hepatitis C in injection drug users. Hepatology 2002;36(Suppl 1):S210-S219. (Pubitemid 35253483)
2. Quaglio GL, Lugoboni F, Pajusco B, et al. Hepatitis C virus infection: prevalence, predictor variables and prevention opportunities among drug users in Italy. J Viral Hepat 2003;10:394-400. (Pubitemid 37159426)
3. Gerlich M, Gschwend P, Uchtenhagen A, Krämer A, Rehm J. Prevalence of hepatitis and HIV infections and vaccination rates in patients entering the heroin-assisted treatment in Switzerland between 1994 and 2002. Eur J Epidemiol 2006;21:545-9.
4. Lidman C, Norden L, Kabera M, et al. Hepatitis C infection among injection drug users in Stockholm Sweden: Prevalence and gender. Scand J Infect Dis 2009 Jun 11:1-6. (Epub ahead of print)
5. Takács IG. HIV- és hepatitiszprevalenciák alakulása az intravénás használók között. (Tendencies of HIV and hepatitis prevalence in intravenous drug users.) In: Felvinczy K, Nyírády A, eds. Drogpolitika számokban. (Drug policy in numbers.) Budapest: L'Harmattan; 2009: 265-268.
6. Reichard O, Norkrans G, Fryden A, Braconier J, Sonnerberg A, Weiland O. Randomised double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-6. (Pubitemid 28026633)
7. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32. (Pubitemid 28510876)
8. Jowett SL, Agarwal K, Smith BC, et al. Managing chronic hepatitis C acquired through intravenous drug use. Q J Med 2001, 94, 153-8. (Pubitemid 32242003)
9. Barrera JM, Bruguera M, Ercilla MG, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21(3):639-44.
10. Cursino-Santos JR, Donadi EA, Martinelli AL, Louzada-Junior P, Martinez-Rossi NM. Evolution of hepatitis C virus infection under host factor influence in an ethnically complex population. Liver Int 2007;27:1371-8.
11. Backmund M, Meyer K, von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001;34:188-193. (Pubitemid 32591499)
12. Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C virus infection in Italian intravenous drug users: epidemiological and clinical aspects. Liver 1995;15:209-212.
13. Editorial: Protocol for the antiviral treatment of hepatitis C. Orv Hetil 2010;151:66-72. (In Hungarian)
14. Renault PF, Hoofnagle JH, Park Y, et al. Psychiatric complications of long-term interferon alpha therapy. Arch Intern Med 1987;147:1577-80.
15. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-51.
16. Eisenberg E, Konopniki M, Veitsman E, Kramskay R, Gaitini D, Baruch Y. Prevalence and characteristics of pain induced by percutaneous liver biopsy. Anesth Analg 2003;96:1392-6.
17. Obled S, Melki M, Coelho J, Coudeyre E, Arpurt JP, Pouderoux P. Patient information for liver biopsy: impact of video movie. Gastroenterol Clin Biol 2007;31:274-8. (Pubitemid 46562328)
18. Coudeyre E, Poiraudeau S, Revel M, Kahan A, Drape JL, Ravaud P. Beneficial effects of information leaflets before spinal steroid injection. Joint Bone Spine 2002;69:597-603. (Pubitemid 36050362)
19. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007;88:49-53. (Pubitemid 46400306)
20. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules. Addiction 2004; 99:1167-75. (Pubitemid 39215278)
21. Tan JA, Joseph TA, Saab S. Treating hepatitis C int he prison population is cost-saving. Hepatology 2008; 48:1387-95.
22. Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health 2010; 100:13-7.